Tumor vaccines for MUC1-positive carcinomas

Details Tumor vaccines for MUC1-positive carcinomas Tumor vaccines for MUC1-positive carcinomas

2008-03-11

2008-03-11

Rawlings, Stephen L. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

15 to 23 amino acid residues in defined sequence

C514S013800

Reexamination Certificate

active

09606910

ABSTRACT:
Tumor vaccines for the use against MUC1 positive carcinomas are presented. A tumor vaccine containing synthetic peptides comprising sequences of the human epithelial mucin MUC1 containing the immunodominat region PDTRPAP which is glycosylated at the threonine. Preferred glycosylation of the immunodominant region is a O-glycosidically linked a-N-acetylgalactosamine (GalNAc) or short chained oligosaccharides. The present invention can be used on all MUC1-positive carcinomas.

REFERENCES:
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6465220 (2002-10-01), Hassan et al.
patent: WO-90/05142 (1990-05-01), None
patent: WO 88/05054 (1988-07-01), None
Osband et al, Immunology Today, 1990, vol. 11, p. 193-195.
Hanisch et al (Cancer Res., 1995, vol. 55(18):4036-40, abstract).
Skolnick J, et al. Trends Biotechnol Jan. 2000; 18 (1): 34-9.
Bowie JU, et al. Science Mar. 16, 1990; 247 (4948): 1306-10.
Yamshchikov G, et al. Clin Cancer Res. Mar. 2001; 7 (3 Suppl): 909s-916s.
Bocchia M, et al. Haematologica. Nov. 2000; 85(11): 1172-206.
Bodey B, et al. Anticancer Res. Jul.-Aug. 2000;20 (4): 2665-76.
Ezzell C. J NIH Res. Jan. 1995; 7: 46-9.
Splitler LE. Cancer Biotherapy, 1995; 10 (1): 1-3.
Lee KH, et al. J Immunol. Dec. 1, 1999; 163 (11): 6292-300.
Boon, T. Adv Cancer Res. 1992; 58: 177-210.
Zaks TZ, et al., Cancer Res. Nov. 1, 1998; 58 (21): 4902-8.
Gao P, et al., J Immunother. Nov.-Dec. 2000; 23 (6): 643-53.
Gura T. Science. Nov. 7, 1997; 278 (5340): 1041-2.
Lu J, et al. Cancer Res. Oct. 15, 2002; 62 (20): 5807-12.
Karsten U, et al., Cancer Res. Jun. 15, 1998; 58 (12): 2541-9.

Affiliated with

Also associated with

Rating

Tumor vaccines for MUC1-positive carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor vaccines for MUC1-positive carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor vaccines for MUC1-positive carcinomas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3958930